

PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM
For asthma therapy: Cinqair (reslizumab)

Please fax form to:
1-866-840-1509

Please note that the patient **AND** physician must complete this form. **All fields are mandatory and must be completed. Incomplete forms may result in your application being declined.** Please retain a copy of this form for your records.

Instructions:

- 1. PLEASE PRINT CLEARLY AND COMPLETE ALL SECTIONS.**
2. The patient/plan member must complete section A.
3. Your physician must complete section B. The cost, if any, of completing this form is at the expense of the patient/plan member.
4. Please return the form to your insurance company via Pharmacy Services at TELUS Health (a service provider of your insurance company) by fax to **1-866-840-1509**.
5. If you have any questions on the application of this program or the decision on reimbursement, or to inquire on the status of your Reimbursement Request Form, please contact your insurer.

A. Information to be Completed by Patient		
Employee or Insured's Name	Drug Card Number ____ - ____ - ____ - ____ - ____	
Patient's Name	Patient's Date of Birth (DD/MMM/YYYY) __ / __ / ____	Relationship to Employee/Insured <input type="checkbox"/> Employee <input type="checkbox"/> Spouse <input type="checkbox"/> Dependent
<p>Please allow two business days for a response once all information is received and complete. Notification of the results of this request will occur Monday to Friday between 9 am and 4 pm Eastern Time.</p>		

Please provide contact information and indicate **ONE** method of preferred contact for notification of the results:

<input type="checkbox"/> E-mail me at:	<input type="checkbox"/> Call me (and leave a message if I'm not there) at:	<input type="checkbox"/> Fax me at:
<input type="checkbox"/> Contact my pharmacy: Pharmacy Name		Pharmacy Phone Number

I certify that the information provided by me is true, correct and complete to the best of my knowledge. I authorize my insurance company, TELUS Health (a service provider of my insurance company), their authorized representatives, agents and service providers to use and exchange this information needed for underwriting, administration and paying claims with any person or organization who has relevant information pertaining to this claim including health professionals, institutions and investigative agencies in the event of an audit. I authorize my insurance company and/or TELUS Health (a service provider of my insurance company) to contact any licensed physician, institution, pharmacy or person who has any records or knowledge of me or my health with respect to this submitted claim.

SIGNATURE OF PATIENT/PARENT/LEGAL GUARDIAN _____

Date: (DD/MMM/YYYY): __ / __ / ____

PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM
For asthma therapy: Cinqair (reslizumab)

Please fax form to:
 1-866-840-1509

B. Information to be Completed by Prescribing Physician

Drug Name	Strength	Dose
Cinqair (reslizumab)		

Cinqair (reslizumab) will be eligible for reimbursement only if the patient satisfies the conditions listed below and if the patient does not qualify for coverage under any other drug plan or government mandated program. If the patient is covered under another drug plan or government mandated program, the prior authorization program, as part of your drug benefits, may cover the portion not paid for by the primary plan. If “None of the above criteria” is indicated, the patient will not be eligible for reimbursement. **For Quebec plan members, please refer to the RAMQ exception drug criteria, if applicable.**

Eligibility Criteria

Please indicate if the patient satisfies the following criteria:

Initial Criteria (approval period of one year):

- Patient has a confirmed diagnosis of severe eosinophilic asthma (T990000023); **AND**
- Cinqair will be used as an add-on maintenance treatment to medium-to-high-dose inhaled corticosteroids (e.g., fluticasone at a dosage of at least 440 µg, or equivalent, daily) and an additional asthma controller(s) (e.g., long-acting beta-agonist); **AND**
- Patient must:
 - Be ≥18 years of age; **AND**
 - Have a blood eosinophil count of ≥400 cells/µL at initiation of the treatment; **AND**
 - Have had at least one asthma exacerbation requiring systemic corticosteroids for at least three days over the past 12 months; **AND**
 - Have persistent airflow obstruction as indicated by a pre-bronchodilator Forced Expiratory Volume in one second (FEV₁) <80% predicted (in the presence of reduced FEV₁/Forced Vital Capacity (FVC) defined as less than the lower limit of normal); **AND**
 - Have airway reversibility of at least 12% to beta-agonist administration; **AND**
 - The patient has an Asthma Control Questionnaire (ACQ) score of at least 1.5; **AND**
- Physician is a respirologist or other specialist in the treatment of asthma; **AND**
- Cinqair will not be used as dual therapy with another monoclonal antibody for the treatment of asthma

Renewal Criteria (approval period of one year):

Treatment with Cinqair has resulted in clinical improvement as demonstrated by one or more of the following:

- Increase in percent predicted FEV₁ from pretreatment baseline; **OR**
- Decreased use of rescue medications from pretreatment baseline; **OR**
- Decreased frequency of exacerbations requiring an increase in inhaled corticosteroid dose or systemic corticosteroids use from pretreatment baseline

OR

- None of the above applies

Relevant additional information _____

PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM
For asthma therapy: Cinqair (reslizumab)

Please fax form to:
1-866-840-1509

Physician Information				
Physician's Name	License Number	Telephone Number	Fax Number	
Address		City	Province	Postal Code
Physician's Signature			Date: (DD/MMM/YYYY) ____ / ____ / ____	